Moderna (NASDAQ:MRNA) has generated terrific gains for investors this year, as the stock has skyrocketed more than 650% entering trading this week. It's been on a tremendous run due to the excitement around its cancer vaccine, intismeran. The vaccine isn't approved yet, however. And that also means the business may be on the cusp of generating significant revenue in the future, due to the promising treatment. Although the stock's up big this year, could investing in Moderna now still enable investors to double their money? Here's why that may not be an unrealistic scenario. Image source: Getty Images.
CryptoAlerta — análise de criptomoedas e mercado em tempo real